Companies /Healthcare

Seres Therapeutics Inc

NASDAQ: MCRB Biotechnology
$1.40
▼ $0.01 (−0.71%) today
Markets closed · 1:28pm ET

MCRB at a Glance

Valuation
Market cap
$13.9M
Profitability
Revenue (TTM)
$2.1M
EPS (TTM)
$-5.01
Price
52-week range
$1 – $30
Street target
$17.00

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: MCRB serestherapeutics.com

About Seres Therapeutics

Seres Therapeutics is a clinical-stage biotechnology company developing oral live biotherapeutics. These are consortia of bacteria manufactured from master cell banks and designed to target the gastrointestinal mucosal epithelial barrier-immune interface. Its programs are in oncology and inflammatory and immune diseases.

The company previously developed VOWST, the first FDA-approved orally administered microbiome therapeutic, and sold the VOWST business to Nestlé Health Science. It received a final [USD:12500000] milestone buy-out payment in October 2026. Current revenue consists solely of grant revenue, including CARB-X support.

Its pipeline includes:
- SER-155 (Breakthrough Therapy and Fast Track designations) for preventing bloodstream infections in allogeneic stem cell transplant patients; Phase 2 ready pending funding.
- SER-155 for preventing immune checkpoint inhibitor-related enterocolitis (irEC); an FDA study design submission is planned for Q1 2027.
- SER-428, a liquid formulation for ICU patients at risk of antimicrobial-resistant infections.
- SER-603 for inflammatory bowel disease, in IND-enabling studies.
- SER-147 for spontaneous bacterial peritonitis in cirrhosis, at the preclinical stage.

The company relies on its AI-enabled MbTx platform for discovery. It is seeking partnerships and capital, with cash runway projected only into Q1 2027. Updated

MCRB Coverage

Frequently Asked Questions

What does Seres Therapeutics do?

Seres Therapeutics is a clinical-stage biotechnology company developing oral live biotherapeutics. These are consortia of bacteria manufactured from master cell banks and designed to target the gastrointestinal mucosal epithelial barrier-immune interface.

What is the MCRB stock price target?

The Wall Street consensus 12-month price target for MCRB is $17.00.